These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24192014)

  • 41. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
    Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
    Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Humoral response and antiviral cytokine expression following vaccination of thoroughbred weanlings--a blinded comparison of commercially available vaccines.
    Gildea S; Quinlivan M; Murphy BA; Cullinane A
    Vaccine; 2013 Oct; 31(45):5216-22. PubMed ID: 24021309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing protection against influenza in children eligible for the vaccine for children program.
    Hull HF; O'Connor H
    Pediatr Infect Dis J; 2010 Oct; 29(10):910-4. PubMed ID: 20431426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A pandemic influenza vaccine in India: from strain to sale within 12 months.
    Dhere R; Yeolekar L; Kulkarni P; Menon R; Vaidya V; Ganguly M; Tyagi P; Barde P; Jadhav S
    Vaccine; 2011 Jul; 29 Suppl 1():A16-21. PubMed ID: 21684421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of vaccines against influenza A virus (H5N1).
    Li WC; Huang YC
    Chang Gung Med J; 2007; 30(4):294-304. PubMed ID: 17939259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influenza vaccines: challenges and solutions.
    Houser K; Subbarao K
    Cell Host Microbe; 2015 Mar; 17(3):295-300. PubMed ID: 25766291
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The status of vaccinal prophylaxis against influenza today].
    Bichurina MA; Fridman EA
    Zh Mikrobiol Epidemiol Immunobiol; 1996; (6):104-8. PubMed ID: 9103060
    [No Abstract]   [Full Text] [Related]  

  • 54. The evolution of poxvirus vaccines.
    Sánchez-Sampedro L; Perdiguero B; Mejías-Pérez E; García-Arriaza J; Di Pilato M; Esteban M
    Viruses; 2015 Apr; 7(4):1726-803. PubMed ID: 25853483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccine adjuvants: the future is bright. Interview by Jenaid Rees.
    Rappuoli R
    Expert Rev Vaccines; 2013 Jul; 12(7):727-9. PubMed ID: 23829664
    [No Abstract]   [Full Text] [Related]  

  • 56. Insect larvae biofactories as a platform for influenza vaccine production.
    Gomez-Casado E; Gomez-Sebastian S; Núñez MC; Lasa-Covarrubias R; Martínez-Pulgarín S; Escribano JM
    Protein Expr Purif; 2011 Sep; 79(1):35-43. PubMed ID: 21421054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dengue virus vaccine development.
    Yauch LE; Shresta S
    Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical experience with inactivated, virosomal influenza vaccine.
    de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
    Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.